What question did this study set out to answer?

This analysis aims to evaluate the impact of the 21-gene Oncotype DX Recurrence Score on chemotherapy decision-making in patients with invasive ductal carcinoma.

July 28, 2026CureusOpen Access

Impact of the 21-Gene Oncotype DX Recurrence Score on Adjuvant Chemotherapy Decision-Making in Invasive Ductal Carcinoma: A Real-World Analysis From a Single Japanese Institution

View Full Paper

Ask AI

Bookmark

Authors

HTHirofumi TerakawaKanazawa University YKYuki KurokawaKanazawa University RMRyosuke MohriKanazawa University Hospital

Discussion

Member takes

Implication

Retrospective analysis reveals genomic testing influences chemotherapy decisions in invasive ductal carcinoma, indicating a shift towards reduced treatment.

Key Points

This analysis aims to evaluate the impact of the 21-gene Oncotype DX Recurrence Score on chemotherapy decision-making in patients with invasive ductal carcinoma.
Conducted a single-center, retrospective, observational study at Kanazawa University Hospital from April 2022 to April 2026.
Patients with HR-positive, HER2-negative IDC who underwent Oncotype DX testing were analyzed, with exclusions for neoadjuvant therapy and incomplete data.
Pathological evaluations were performed locally according to ASCO/CAP guidelines.
Out of 140 patients, 102 were included; median age was 55, with 59.8% postmenopausal and 62.7% node-negative.
Clinico-genomic discordance rate was 57.8% (95% CI, 48.1-67.0), with high clinical risk but low genomic risk found in 52.9% of cases.
Adjuvant chemotherapy was omitted in 77.3% of clinically high-risk patients, emphasizing the role of genomic testing in decision-making.

Cite This Study

Terakawa et al. (2026) studied this question.

synapsesocial.com/papers/6a6850eb2845b684d16f0051 https://doi.org/10.7759/cureus.113358

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals genomic testing influences chemotherapy decisions in invasive ductal carcinoma, indicating a shift towards reduced treatment.

Impact of the 21-Gene Oncotype DX Recurrence Score on Adjuvant Chemotherapy Decision-Making in Invasive Ductal Carcinoma: A Real-World Analysis From a Single Japanese Institution

Discussion

Member takes

Implication

Key Points

Cite This Study

Impact of the 21-Gene Oncotype DX Recurrence Score on Adjuvant Chemotherapy Decision-Making in Invasive Ductal Carcinoma: A Real-World Analysis From a Single Japanese Institution

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider